# The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study

> **NCT02793128** · PHASE3 · COMPLETED · sponsor: **UroGen Pharma Ltd.** · enrollment: 71 (actual)

## Conditions studied

- Carcinoma, Transitional Cell
- Transitional Cell Carcinoma of Renal Pelvis

## Interventions

- **DRUG:** UGN-101 instillations

## Key facts

- **NCT ID:** NCT02793128
- **Lead sponsor:** UroGen Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-04
- **Primary completion:** 2019-04-05
- **Final completion:** 2020-03-05
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2020-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02793128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02793128, "The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02793128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*